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Treatment of Malignant Biliary
Obstruction with a PTFE-Covered Self-
Expandable Nitinol Stent 
Objective: We wanted to determine the technical and clinical efficacy of using
a PTFE-covered self-expandable nitinol stent for the palliative treatment of malig-
nant biliary obstruction. 
Materials and Methods: Thirty-seven patients with common bile duct strictures
caused by malignant disease were treated by placing a total of 37 nitinol PTFE
stents. These stents were covered with PTFE with the exception of the last 5 mm
at each end; the stent had an unconstrained diameter of 10 mm and a total length
of 50 80 mm. The patient survival rate and stent patency rate were calculated by
performing Kaplan-Meier survival analysis. The bilirubin, serum amylase and
lipase levels before and after stent placement were measured and then com-
pared using a Wilcoxon signed-rank test. The average follow-up duration was
27.9 weeks (range: 2 81 weeks).
Results: Placement was successful in all cases. Seventy-six percent of the
patients (28/37) experienced adequate palliative drainage for the remainder of
their lives. There were no immediate complications. Three patients demonstrated
stent sludge occlusion that required PTBD (percutaneous transhepatic biliary
drainage) irrigation. Two patients experienced delayed stent migration with stone
formation at 7 and 27 weeks of follow-up, respectively. Stent insertion resulted in
acute elevations of the amylase and lipase levels one day after stent insertion in
11 patients in spite of performing endoscopic sphincterotomy (4/6). The bilirubin
levels were significantly reduced one week after stent insertion (p < 0.01). The
30-day mortality rate was 8% (3/37), and the survival rates were 49% and 27% at
20 and 50 weeks, respectively. The primary stent patency rates were 85%, and
78% at 20 and 50 weeks, respectively.
Conclusion: The PTFE-covered self-expandable nitinol stent is safe to use
with acceptable complication rates. This study is similar to the previous studies
with regard to comparing the patency rates and survival rates.
he treatment for malignant biliary obstruction includes performing
surgery and interventional procedures such as insertion of a self-expand-
ing metal stent under fluoroscopic and/or endoscopic guidance (1 6).
Self-expanding metal stents have become a well-accepted palliative procedure for
relieving inoperable malignant biliary obstruction. The most common causes of
occlusion of an uncovered stent are sludge formation, proximal and distal tumor
overgrowth, tumor ingrowth and stone formation (1, 7, 8). The obstruction rates for
uncovered stents in a previous study varied from 5% to 100% (mean: 22%) during a
0.7 to 19 month period following stent placement (9). 
To improve the patency rates of metallic stents, many studies have been performed
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Tto investigate polyurethane- and expanded polytetrafluo-
roethylene-fluorinated ethylene propylene (ePTFE-FEP)-
covered stents (10 20). The obstruction rate for these
covered stents has varied from 0% to 37% (mean rate:
15%). The cause of polyurethane-covered stent occlusion
was previously reported to be due to a degraded
polyurethane membrane and subsequent tumor ingrowth
into the stent (10). In animal studies, PTFE has been shown
to be quite useful for reconstructing the common bile duct
(21). Schoder et al. reported that using an ePTFE-FEP
covered stent produced good clinical results with no stent
obstruction; this type of stent has anchoring fins at its ends
(19). We hypothesized that a PTFE membrane forms a
successful barrier against future tumor ingrowth, and so
this might improve the stent patency rates. 
We present here the results of a pilot study of implanting
PTFE-covered Niti-S stents in patients suffering with
malignant biliary obstruction. This is a prospective, non-
randomized clinical study that’s intended to determine the
technical efficacy and safety of implanting a PTFE-covered
self-expandable nitinol stent for the management of
malignant biliary obstruction. We evaluated the clinical
efficacy of this stent design by determining the stent
patency rate and the patient survival rate. 
MATERIALS AND METHODS
Patient Population
Thirty-seven subjects were enrolled in this study; there
were 19 men and 18 women with a mean age of 70 years
(age range: 47 85 years). The study protocol was
approved by the Institutional Review Board of our univer-
sity and also by the Ethics Committee of the Institute for
Medical Science. The procedure was explained in detail to
all the prospective patients, and a written consent was
obtained from all the subjects before the procedure. The
study inclusion criteria were (i) the presence of malignant
obstruction of the common bile duct below the hilar
confluence, and this was caused by unresectable malignant
tumor or reocclusion of a previously inserted self-expand-
able uncovered biliary stent, and (ii) obtaining an informed
consent. The exclusion criteria included surgical resectabil-
ity of the tumor, hilar obstruction or postoperative anasto-
motic site obstruction due to malignant recurrence, or the
presence of a generally fatal patient condition such as
sepsis or disseminated intracoagulopathy. Thirty-seven
patients had percutaneous biliary drainage performed, of
which 34 were treated with a covered stent as the first
stent, and three were treated for failure of a standard
uncovered stent. Six patients underwent sphincterotomy
via endoscopic guidance before stent insertion. 
In our study, 14 patients had biopsy-confirmed
adenocarcinomas and 23 patients lacked a confirming
biopsy, but these 23 patients had been diagnosed by the
findings on abdominal spiral computed tomography (CT),
magnetic resonance (MR) imaging, percutaneous cholan-
giography and endoscopic retrograde cholangiopancreatog-
raphy (ERCP). Thirteen patients had common bile duct
carcinoma, eight patients had pancreatic head carcinoma,
four patients had gallbladder carcinoma, six patients had
periampullary carcinoma and six patients had gastric
carcinoma. The site of obstruction was the proximal
common bile duct (CBD) in three patients, the middle
CBD in six patients and at the distal CBD in 28 patients.
Stent Device and Placement
The stents used in this study were self-expanding biliary
PTFE covered Niti-S stents (Taewoong Medical
Corporation, Seoul, Korea), as are described in Figure 1.
The Niti-S stent we used was made of 0.007-inch single
nitinol wire, which has excellent biocompatibility and
expansile force, and the stent was also self-expanding
without any sharp spurs at either end (low trauma ends). 
To prevent stent migration, a PTFE membrane covered
the stent on the inside of the metal wire. Thus, the outer
surface of the stent had a rough texture. The stents were
5 8 cm long when fully expanded to a maximum
diameter of 10 mm, and they were positioned using a 9-Fr
introducer system. The stent was held, compressed and
elongated on the delivery catheter by a cylindrical rolling
membrane (the outer sheath). The delivery catheter had
three markers: one at a first-proximal portion (the
proximal marker), the second at the actual stent length
position (the stent length marker), and the third at the
distal position of the loaded stent (the stent marker). Stent
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Fig. 1. The PTFE-covered self-expanding Niti-S stent endopros-
thesis. The stent is a woven, monofilament structure composed of
nitinol, and it is covered on its interior surface by PTFE.deployment was accomplished by withdrawing the outer
sheath while fixing the inner catheter. The devised Niti-S
stent became shortened by 51% after deployment, which
is similar to that of Wallstents (50%); the Nitis-S stent had
tungsten markers on its proximal and distal ends that
helped with manipulation during deployment (13).
Fluoroscopic Guidance Procedure
The fluoroscopic guidance procedure was performed as
previously described by Han et al. (20). In most patients,
stent placement was accomplished within two weeks after
performing percutaneous transhepatic biliary drainage
(PTBD). Stent placement was accomplished in three
patients during the follow-up tubogram after protracted
PTBD or stent placement. A right intercostal and/or left
epigastric approach was chosen depending on the extent of
tumor. Stent insertion was performed over an extra stiff
Amplatz guidewire (180 cm, 0.035 inch, curved tip; Cook
Inc., Bloomington, IN). Care was taken to precisely locate
the covered mid-portion of the stent exactly at the
stricture. The distal end of the stent protruded 2 3 mm
into the duodenum. Balloon dilation after stent insertion
was not performed in any of our patients; instead, an 8.5-
Fr or 10.2-Fr biliary drainage catheter was left in place for
seven days. This catheter was used only for flushing and
maintaining access to the biliary tree, and not for drainage.
Thereafter, imaging was repeated via the drainage catheter
to check the stent’s patency, function and position. The
catheter was removed if free bile flowing into the
duodenum was documented or if the bilirubin level was
normalized or markedly reduced.
All the patients received 200 mg of prophylactic antibi-
otics that were administered intravenously over a period of
12 hours (Flomoxef sodium; Flumarin , Ildong, Ansung,
Korea; or Fosfomycin sodium; Fonofos , Chong Keun
Dang, Chunan, Korea) before and usually 48 72 hours
after the procedure. Coagulation tests were performed
before the procedure, and if a patient had disseminated
intravascular coagulopathy, then stent placement was not
performed. 
Study Endpoints and Definitions
A hospital discharge report was obtained for each
patient. The study endpoints were followed at monthly
intervals for two years. Sonography of the upper abdomen
was performed, and the bilirubin levels were checked at
each examination. The patients were also followed by
conducting telephone interviews with the referring
physicians or with the patients when the patients failed to
appear at the follow-up examinations. If stent occlusion
was suspected, then the stent was revised percutaneously
using a 10-Fr drainage catheter. Finally, the cause of death
was ascertained for all the patients who died within the
observation period.
Successful decompression of the biliary system was
defined by a decrease of the serum bilirubin level of more
than 30% versus the baseline value within a week of stent
insertion (10). We measured the distance from the
bifurcated line between the right and left intrahepatic ducts
to the end of the biliary stent. Stent migration was divided
into proximal and distal stent migration. Proximal stent
migration was defined as a stent that migrated into the
common hepatic duct, and distal stent migration was
defined as a stent that migrated into the duodenum or out
of the patient’s body. The extents of these migrations were
established by comparing the stent ends with the stent
positions seen on the initial images. Early migration was
defined as migration that occurred within one week of
deployment, and delayed migration was defined as
migration that occurred from one week to one month after
stent placement. For the cases of recurrent jaundice, any
stent occlusion was confirmed by sonography or CT, which
showed dilation of the intrahepatic duct and the presence
of soft tissue density inside the stent. Recurrent episodes of
inexplicable fever were defined as cholangitis. At the time
of death, a stent was assumed to be patent if the patient
had normal or only mildly elevated serum bilirubin levels
(< 3 mg/dl). If the patients had obvious jaundice or if they
had a higher bilirubin level than that before stent
placement, then the stent was assumed to be obstructed.
Ultrasonography (US) was used to examine the degree of
stent occlusion. Echogenic materials in the stents, as were
determined by US, were considered to represent sludge,
and floating material in the stent, as determined by
percutaneous transhepatic cholangiography, was also
considered to represent sludge formation.
The bilirubin and amylase/lipase levels before and during
follow-up were statistically analyzed by using the
Wilcoxon signed-rank test. The stent patency rate and the
patient survival rate were calculated by performing
Kaplan-Meier survival (life-table) analysis. The duration of
primary patency was defined as the interval between stent
placement and the recurrence of obstructive jaundice. If
obstruction was not evident during a patient’s life, then the
patency period was considered to be equal to the survival
duration, but this data was censored. 
RESULTS
Stent deployment was successful in all 37 patients, and
this was performed via transpapillary placement of the
covered stent (37/37, 100%) (Fig. 2). No proximal or distal
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patients showed that the stent had migrated completely out
of the biliary duct during the 7-week and 27-week follow-
up period, respectively. The distance between the
bifurcated line and the end of the stent immediately after
stent placement was 6 35 mm (mean: 15 mm). One week
later, follow-up tubography showed no change of this
distance (range: 6 35 mm: mean: 15 mm). The follow-up
plain films showed no changes in any of the stents in the
right upper quadrant areas except for two patients who
experienced delayed stent migration. 
The mean bilirubin level decreased from 11.1 mg/dL
6.86 standard deviation (SD) before the procedure to 5.12
mg/dL 4.6 SD at the first follow-up, and this difference
was statistically significant (Wilcoxon test: p < 0.01).
Significant changes in the bilirubin levels were observed
between the baseline and the most recent follow-up after
stent placement (p < 0.05). The amylase and lipase levels
were 110.5 IU/L 150.6 and 133.4 IU/L 187.3, respec-
tively, before the procedure; they were 94.0 IU/L 90.6
and 135.2 IU/L 185.0, respectively, one week after the
procedure, and they were 48.6 IU/L 38.1 and 50.3 IU/L
54.2, respectively, at the last follow-up (Fig. 3). The
amylase and lipase levels did not increase at one week and
at the last follow-up day after the insertion (p > 0.01). The
amylase and lipase levels were found to be severely
elevated one day after stent insertion in 11/37 patients
(29%); that is, the amylase/lipase level was 505 IU/L
(range: 107 1,455)/520 IU/L (range: 77 1,019). Despite
endoscopic sphincterotomy that was done in six patients,
four patients revealed severe elevations of their amylase
and lipase levels one day after stent insertion. These 11
patients had pancreatitis symptoms such as pain; however,
their amylase and lipase levels stabilized within seven
days. The 30-day mortality rate was 8% (3/37), which
reflected fatal septic conditions in two patients and death
from an unknown cause in one patient. Three patients
showed good patency of their biliary stent, according to
one-week follow-up ultrasound sonography. However, the
bilirubin level of two patients before stent insertion was
from 11.0 mg/dl to 11.5 mg/dl and 13.5 mg/dl to 14.4
mg/dl, respectively, on the one-week follow-up, and one
other patient showed a bilirubin level from 24.7 mg/dl to
22.0 mg/dl. The discrepancies between the image findings
and lab findings were related to each patient’s conditions. 
The lesion was completely covered by the stent in four
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Fig 3. The graph shows the changes of the amylase and lipase
level before and after stent placement and during the last follow-
up. 
Fig. 2. A 68-year-old female with
common bile duct carcinoma.
A. The tubogram taken immediately
after stent insertion shows good stent
patency and correct positioning. 
B. This one-week follow-up tubogram
shows good stent function. The distance
between the end of the stent and the
bifurcation of the common hepatic duct
shows no change. 
ABpatients who received a 5-cm-long stent, in 12 patients
who received a 6-cm-long stent, in 11 patients who
received a 7-cm-long stent, in nine patients who received
an 8-cm-long stent and in one patient who received a 9-
cm-long stent. The stent was sufficiently long to cover the
lesion in all the patients. No case of biliary side-branch
obstruction occurred, except for at the cystic duct. 
Seventy-six percent (28/37) of the study patients experi-
enced adequate palliative drainage for the remainder of
their lives. Three patients displayed stent sludge occlusion,
and PTBD showed some filling defect in these stents (Fig.
4). However, good stent patency was achieved via irriga-
tion for two patients who both underwent PTBD two times
during the follow-up. Two patients had PTBD performed:
Han et al.
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ABC
Fig. 5. A 76-year-old female with
Ampulla of Vater carcinoma. 
A. The five-day follow-up plain film after
stent insertion shows good stent
positioning on the air-biliary gram
(arrows). 
B. The 27-week follow-up tubogram
after percutaneous transhepatic biliary
drainage shows no evidence for the
presence of a stent, and there is a small
filling defect in the distal common bile
duct, which may be a common bile duct
stone (arrows). 
AB
Fig. 4. A 78-year-old female with common bile duct carcinoma. 
A. The one-week follow-up tubogram shows a well functioning stent. 
B. This 33-week follow-up tubogram after percutaneous transhepatic biliary drainage shows no contrast medium, due to food reflux, in
the stent (arrows).
C. The tubogram after stent irrigation shows good passage of contrast medium into the duodenum. Small remnants of food material
(arrows) were observed in the left intrahepatic duct and in the distal portion of the stent. one patient due to tumor ingrowth (34 weeks) and another
due to stent migration (7 weeks). One patient had biliary
obstruction 27 weeks after stent insertion. The tubogram
finding after PTBD showed stone formation, but we did
not find the previously inserted PTFE stent in the abdomen
(Fig. 5). One patient underwent percutaneous transhepatic
gallbladder drainage at 19 weeks due to acute cholecystitis,
and that patient also underwent PTBD at 24 weeks due to
overgrowth that was noted at 24 weeks. Two patients had
percutaneous transhepatic gallbladder drainage due to
acute cholecystitis.
The duration of the follow-up study for all the patients
was 2 81 weeks (mean: 27.9 weeks). Twenty-eight
patients died during 2 81 weeks and nine patients lived
until 43 80 weeks. According to the Kaplan-Meier
survival analysis, the primary stent patency rates were
85% and 78% at 20 and 50 weeks, respectively; the
survival rates were 49% and 27% at 20 and 50 weeks,
respectively; and the mean survival and patency durations
were 33 weeks and 64 weeks, respectively. No procedure-
related patient deaths were identified, and all the deaths
were attributed to the patients’ natural course of disease.
The covered stents showed patent lumens in 28 patients;
this was confirmed by such laboratory values as the biliru-
bin levels at the final follow-up. 
DISCUSSION
The reported follow-up durations and patency rates of
covered stents in the medical literature have varied (10
19). Hausegger et al. (10) have reported that the patency
rates after 1, 3, 6 and 12 months were 96%, 69%, 47%
and 31%, respectively. Rossi et al. (16) have reported
primary patency rates after 3, 6 and 9 months of 72%,
46% and 46%, respectively. Both of these investigations
(10, 16) didn’t report good patency rates because their
stent occlusion rates were somewhat high (33 37%). Born
et al. (14) noted that the mean survival of their patients
was six months. Kanasaki et al. (12) reported that the
mean patency period of their stents was 37.5 weeks.
Schoder et al. (19), in a large series of covered stents,
reported the primary patency rates at 3, 6 and 12 months
to be 90%, 76% and 76%, respectively, and we
previously reported stent patency rates of 71% and 48%
at 20 and 50 weeks, respectively (20). In this present
study, the primary and stent patency rates were 85%, and
78% at 20 and 50 weeks, respectively. Kanasaki et al. (12)
and Born et al. (14) have reported good patency rates that
were the result of lower stent occlusion rates. However,
making comparison with those studies is difficult because
each of their patients was treated at a different stage of
disease, and the tumors differed for their histologic type,
cellular growth and biological behavior (12). 
The ePTFE/FEP-covered stent has several advantages. It
is resistant to bacterial growth, and this reduces the risk of
occlusion caused by bile incrustation (18, 22). Moreover,
PTFE resists chemicals (acids and alkalies) and heat, and
PTFE is self-lubricating and not prone to demolding.
Moreover, although PTFE has a low coefficient of friction
and therefore good patency, it has poor adhesion to other
materials (23). In the present study, the PTFE stent offered
several advantages. First, a 9-Fr introducer system was
used for implanting the PTFE-covered stents, which is a
much smaller system than that required for the Schoder et
al. ePTFE-FEP covered stent. Second, in order to prevent
stent migration, the end portion of the stent and the
outside of the stent are not coated with PTFE. Third, the
stent is designed to be covered with PTFE on the inner
aspect of the stent. The stent wire surrounds the PTFE, and
so the stent’s outer surface is similar to that of an
uncovered stent. In our study, two patients experienced
delayed stent migration.
The disadvantage of the ePTFE/FEP-covered stent is that
the fabric covering of the expanded stent may cause
blockage of the cystic or pancreatic duct, and this can
result in possible cholecystitis or pancreatitis (18, 19). In
our study, three patients (3/37, 8%) underwent percuta-
neous transhepatic gallbladder drainage due to acute
cholecystitis. The most obvious disadvantage of the PTFE
stent was that stent insertion was followed by marked
elevation in the amylase and lipase levels one day after
insertion; these levels subsequently decreased and then fell
to normalized levels within seven days. The other
disadvantage of the stent is the occurrence of stent obstruc-
tion due to sludge formation. In our opinion, this elevation
of the amylase and lipase levels was caused by pancreatic
sphincter hypertension because there was no space
between the stent and the sphincter of Oddi, as seen on
post-endoscopic retrograde cholangiopancreatography
(ERCP). The level of the lesion was the proximal CBD in
one patient, the mid CBD in two patients and the distal
CBD in eight patients. The cause of disease was CBD
carcinoma in three patients, gastric carcinoma in three
patients, ampulla of Vater carcinoma in two patients and
pancreatic head carcinoma in three patients. Four patients
underwent endoscopic sphincteromy. The second
disadvantage of stenting is the possibility of stent occlusion
due to food reflux from the duodenum into the proximal
common bile duct.
There are many studies that have made comparisons
between covered and uncovered stents (24 26). Isayama
et al. reported have that covered stents successfully
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superior to uncovered stents for treating those patients
suffering with distal malignant biliary obstruction (24).
Stent occlusion occurred in covered stents for eight
patients (14%) after a mean of 304 days (24). Yoon et al.
reported that the stent patency rates were 83%, 78%,
67% and 54% at 100, 200, 300 and 400 days, respec-
tively, for covered stents and 83%, 66%, 54% and 36%,
respectively, for uncovered stents, which was not signifi-
cantly different (25). Stent migration occurred in three
patients (3/36, 8%) in that study. Park et al. have reported
that the mean stent patency was 148.9 days for covered
stents and 143.5 days for uncovered stents. The incidence
of mild pancreatitis was 6.1% for covered stents and 1.9%
for uncovered stents (26). Migration of stent occurred in
0.6% of the patients and sludge formation in stents
occurred in 20% of the patients in the above study. In our
study, the covered stent showed similar patency rates, a
high incidence of mild pancreatitis and a low incidence of
sludge formation and stent migration.
Our study has a few limitations. The study group was a
somewhat small compared to other related studies. One
patient had tumor ingrowth in the mid portion of their
stent; however, the image finding was not confirmed by
choledochoscopy. Tumor ingrowth may not occur in PTFE
materials because the PTFE itself is a strong barrier. If it
does occurs, it would be due to damage or natural degrada-
tion of PTFE.
In conclusion, the PTFE-covered self-expandable nitinol
stent is safe with acceptable complication rates. This study
is similar to previous studies in regard to comparing
between the patency rates and the survival rates. Using the
PTFE-covered self-expandable nitinol stent for treating
malignant biliary obstruction was found to be a feasible
and effective means of achieving biliary drainage. 
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